Author

André G. Deslauriers

Novo Nordisk (Denmark)ORCID 0000-0002-2854-5681Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Ann-Charlotte BjörklundiD· 1 shared Dimitris C. KanellisiD· 1 shared Eirini P. PapapetrouiD· 1 shared Elli PapaemmanuiliD· 1 shared Eva Hellström‐LindbergiD· 1 shared Gabriele TodiscoiD· 1 shared Indira BarbosaiD· 1 shared Ingrid LilienthaliD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ann-Charlotte BjörklundORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedAug 26, 2025

SF3B1-mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition

Jonas Thier, Sophia Hofmann, Katharina Miria Kirchhof…·Vanessa Lundin

This study identifies UBA1 mis-splicing as a therapeutic target in SF3B1-mutant myelodysplastic syndromes, showing that UBA1 inhibition sensitizes these cells to treatment.

4 citations

humanbulk RNA-seq

𝕏 PostBluesky